183 related articles for article (PubMed ID: 11585010)
1. Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.
Owen RG
Expert Opin Pharmacother; 2001 Jun; 2(6):945-52. PubMed ID: 11585010
[TBL] [Abstract][Full Text] [Related]
2. Alkylating agents for Waldenstrom's macroglobulinaemia.
Yang K; Tan J; Wu T
Cochrane Database Syst Rev; 2009 Jan; (1):CD006719. PubMed ID: 19160296
[TBL] [Abstract][Full Text] [Related]
3. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders.
Tallman MS; Hakimian D
Blood; 1995 Oct; 86(7):2463-74. PubMed ID: 7670093
[No Abstract] [Full Text] [Related]
4. Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
O'Brien S; Kantarjian H; Keating MJ
Ann Oncol; 1996; 7 Suppl 6():S27-33. PubMed ID: 9010576
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine in Waldenstrom's macroglobulinemia.
Leblond V; Choquet S
Semin Oncol; 2003 Apr; 30(2):239-42. PubMed ID: 12720144
[TBL] [Abstract][Full Text] [Related]
6. Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?
Ling S; Joshua DE; Gibson J; Young G; Iland H; Watson G; Ho PJ
Am J Hematol; 2006 Feb; 81(2):110-4. PubMed ID: 16432856
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine in Waldenstrom's macroglobulinemia.
Souchet-Compain L; Nguyen S; Choquet S; Leblond V
Expert Rev Hematol; 2013 Jun; 6(3):229-37. PubMed ID: 23782076
[TBL] [Abstract][Full Text] [Related]
8. New prospects in the treatment of indolent lymphomas with purine analogues.
Cheson BD
Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S27-36. PubMed ID: 9672772
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine-based combination therapies for Waldenström's macroglobulinemia.
Tedeschi A; Alamos SM; Ricci F; Greco A; Morra E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):67-70. PubMed ID: 19362977
[TBL] [Abstract][Full Text] [Related]
10. Waldenström's macroglobulinemia.
Desikan KR; Dhodapkar MV; Barlogie B
Curr Treat Options Oncol; 2000 Jun; 1(2):97-103. PubMed ID: 12057047
[TBL] [Abstract][Full Text] [Related]
11. Waldenström's macroglobulinemia.
McKenna JA
Clin J Oncol Nurs; 2002; 6(5):283-6. PubMed ID: 12240489
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Dimopoulos MA; O'Brien S; Kantarjian H; Estey EE; Keating MJ; Alexanian R
Leuk Lymphoma; 1993; 11 Suppl 2():105-8. PubMed ID: 7907250
[TBL] [Abstract][Full Text] [Related]
13. Waldenström's macroglobulinaemia.
Johnson SA; Oscier DG; Leblond V
Blood Rev; 2002 Sep; 16(3):175-84. PubMed ID: 12163003
[TBL] [Abstract][Full Text] [Related]
14. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
Johnson SA; Owen RG; Oscier DG; Leblond V; Levy V; Jaeger U; Seymour JF
Clin Lymphoma; 2005 Mar; 5(4):294-7. PubMed ID: 15794869
[TBL] [Abstract][Full Text] [Related]
15. Waldenström's macroglobulinemia: a review of therapy.
Gertz MA
Leuk Lymphoma; 2002 Aug; 43(8):1517-26. PubMed ID: 12400593
[TBL] [Abstract][Full Text] [Related]
16. Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Zinzani PL; Tani M; Alinari L; Stefoni V; Baccarani M
Leuk Res; 2003 May; 27(5):465-6. PubMed ID: 12620298
[No Abstract] [Full Text] [Related]
17. Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies.
Saven A
Semin Hematol; 1993 Oct; 30(4 Suppl 6):31-3. PubMed ID: 7908757
[No Abstract] [Full Text] [Related]
18. Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
Peinert S; Seymour JF
Leuk Lymphoma; 2010 Oct; 51(10):1767-70. PubMed ID: 20919859
[No Abstract] [Full Text] [Related]
19. Perspectives on purine analogues.
Cheson BD
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S109-16. PubMed ID: 9137964
[TBL] [Abstract][Full Text] [Related]
20. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.
Rourke M; Anderson KC; Ghobrial IM
Leuk Lymphoma; 2010 Oct; 51(10):1779-92. PubMed ID: 20795787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
